The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: A noninferiority phase III trial (SAKK 96/12, REDUSE).
Arnoud J. Templeton
No relevant relationships to disclose
Lukas Stalder
No relevant relationships to disclose
Juerg Bernhard
No relevant relationships to disclose
Peter Brauchli
No relevant relationships to disclose
Silke Gillessen
Consultant or Advisory Role - Novartis
Stefanie Hayoz
No relevant relationships to disclose
Dirk Klingbiel
No relevant relationships to disclose
Klazieu Matter-Walstra
No relevant relationships to disclose
Beat J. K. Thurlimann
Stock Ownership - Novartis
Roger Von Moos
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen